Screening of interstitial lung disease in patients with rheumatoid arthritis: A systematic review.
Artritis reumatoide
Cribado
Enfermedad pulmonar intersticial
Interstitial lung disease
Revisión sistemática
Rheumatoid arthritis
Screening
Systematic review
Journal
Reumatologia clinica
ISSN: 2173-5743
Titre abrégé: Reumatol Clin (Engl Ed)
Pays: Spain
ID NLM: 101717526
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
22
01
2021
accepted:
27
07
2021
pubmed:
16
11
2021
medline:
30
11
2022
entrez:
15
11
2021
Statut:
ppublish
Résumé
Interstitial lung disease (ILD) is frequent in patients with rheumatoid arthritis (RA) and is associated with significant morbidity and mortality. The aim of this review was to identify the different screening methods for ILD in patients with RA. We ran a systematic search in Pubmed, Embase and Cochrane Library up to April 2020 and did a hand search of the references of the retrieved articles. The search was limited to humans and articles published in English, Spanish or French. We selected studies with any design where: (a) the population included adult patients with RA; (b) the intervention was any screening method for ILD; and (c) validity or reliability of the screening method were evaluated, or a screening method was described. Two reviewers independently screened the articles by title and abstract and subsequently extracted the information using a specific data extraction form. 25 studies were included with a total of 2593 patients. The most frequently used tool for ILD screening was high resolution computed tomography (HRCT) of the lung. Electronic auscultation, biochemical markers, bronchoalveolar lavage (BAL), pulmonary function tests (PFTs) and lung ultrasonography were also evaluated. Across the different studies, electronic auscultation and lung ultrasonography achieved higher accuracy than PFTs, BAL and biochemical markers. HRCT resulted as the most sensitive tool for ILD screening in patients with RA. Given its harmlessness and high sensitivity, lung ultrasonography may become the first-choice tool in the future.
Identifiants
pubmed: 34776393
pii: S2173-5743(21)00194-5
doi: 10.1016/j.reumae.2021.07.002
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
587-596Informations de copyright
Copyright © 2021 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.